BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the ...

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong ...

We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best small cap pharma stocks to buy right now. TheFly reported on May ...

BioAge Labs' stock recently jumped, and a Wall Street analyst thinks it has further to climb. The company is focusing on a source of inflammation in the brain as a way to regulate appetites. A new ...

Sept 26 (Reuters) - Shares of BioAge Labs (BIOA.O), opens new tab opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the ...

The drugs Wegovy from Novo Nordisk and Zepbound from Eli Lilly both limit appetite by targeting GLP-1 receptors in the pancreas. Global sales of GLP-1 drugs are expected to reach $95 billion annually ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and ...

The combination of an experimental BioAge Labs drug with the approved Eli Lilly obesity medication Zepbound has hit a major setback: a safety signal observed in some clinical trial participants that ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) - Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its ...

As a rule, clinical-stage biotech companies are high-risk investments. But they aren't all the same. The more positive clinical trial results they have for their candidates, the less speculative they ...

BioAge now offering 10.5 mln shares, vs 7.5 mln earlier Sofinnova expected to invest up to $1.4 mln in IPO Investment firm expected to buy shares worth $10.6 mln in private placement Sept 25 (Reuters) ...